Imris (OTCMKTS:IMRSQ – Get Free Report) and Delcath Systems (NASDAQ:DCTH – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Imris and Delcath Systems, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Imris | 0 | 0 | 0 | 0 | 0.00 |
| Delcath Systems | 1 | 1 | 5 | 0 | 2.57 |
Delcath Systems has a consensus price target of $22.17, suggesting a potential upside of 81.40%. Given Delcath Systems’ stronger consensus rating and higher probable upside, analysts plainly believe Delcath Systems is more favorable than Imris.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Imris | N/A | N/A | N/A |
| Delcath Systems | 0.62% | 0.51% | 0.46% |
Earnings and Valuation
This table compares Imris and Delcath Systems”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Imris | N/A | N/A | N/A | N/A | N/A |
| Delcath Systems | $85.23 million | 4.95 | $2.70 million | $0.01 | 1,222.00 |
Delcath Systems has higher revenue and earnings than Imris.
Insider & Institutional Ownership
61.1% of Delcath Systems shares are held by institutional investors. 19.4% of Delcath Systems shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Delcath Systems beats Imris on 9 of the 9 factors compared between the two stocks.
About Imris
IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Receive News & Ratings for Imris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imris and related companies with MarketBeat.com's FREE daily email newsletter.
